The NLRP3 inflammasome and diabetic cardiomyopathy

Cardiovascular Drugs and Therapy

Volumn 28, Issue 1, 2014, Pages 5-6

  Singh, Lalit P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; FLUOROBENZENES; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES;

EID: 84898799055     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6501-x     Document Type: Editorial

References (16)

1. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11(2):136-40.
2. Oslowski CM, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M, et al. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab. 2012;16(2):265-73.
3. Lupfer C. Kanneganti TDUnsolved mysteries in NLR biology. Front Immunol. 2013;4:285.
4. Mankan AK, Dau T, Jenne D, Hornung V. The NLRP3/ASC/ Caspase-1 axis regulates IL-1β processing in neutrophils. Eur J Immunol. 2012;42(3):710-5.
5. Luo B, Li B, Wang W, Liu X, Liu X, Xia Y, Zhang C, Zhang Y, Zhang M, An F. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther 2014;28: this issue
6. McGettrick AF, O'Neill LA. NLRP3 and IL-1β in macrophages as critical regulators of metabolic diseases. Diabetes Obes Metab. 2013;15(Suppl 3):19-25.
7. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787-91.
8. Sbai O, Devi TS,Melone MA, Feron F, KhrestchatiskyM, Singh LP, et al. RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression and cytokine secretion. J Cell Sci. 2010;123(Pt 24):4332-9.
9. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905-15.
10. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin- 1βantibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013;S1262-3636(13)00130-4.
11. Dinarello CA, Simon A, van derMeer JW. Treating inflammation by blocking interleukin-1 in a broad spectrumof diseases. Nat Rev Drug Discov. 2012;11(8):633-52.
12. Xu G, Chen J, Jing G, Shalev A. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med. 2013;19(9):1141-6.
13. Chen J, Cha-Molstad H, Szabo A, Shalev A. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin- interacting protein. Am J Physiol Endocrinol Metab. 2009;296(5):E1133-9.
14. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010;1:e65.
15. Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol. 2009;221(1):262-72.
16. Blouet C, Liu SM, Jo YH, Chua S, Schwartz GJ. TXNIP in Agrp neurons regulates adiposity, energy expenditure, and central leptin sensitivity. J Neurosci. 2012;32(29):9870-7.